STOCK TITAN

Cerenome Reports Interim ReSPECT-LM Data Supporting Repeat Dosing of REYOBIQ™ in Leptomeningeal Metastases at the 2026 SNO Annual Meeting

(Very High)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Cerenome (CNSY) reported interim Phase 1 ReSPECT-LM results from 10 patients receiving repeated REYOBIQ doses for leptomeningeal metastases, cancer involving brain and spinal cord membranes. No dose-limiting toxicities or adverse events causing discontinuation were reported; one patient had Grade 3 treatment-related nausea. One patient received three 26.4 mCi doses, totaling 79.2 mCi, exceeding the prior single-dose study's highest administered activity of 75 mCi.

No LM progression was documented among evaluable patients at three or six months (0/5 each); progression occurred in 1/4 by nine months. Radiation delivery varied by a median of 8% within patients across doses. These preliminary, open-label findings do not establish a progression-free or overall survival benefit. Dose escalation continues. Cerenome targets a randomized Phase 2 study in 2027, subject to continued clinical progress and regulatory alignment.

Loading...
Loading translation...
10 points · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

0 major · 6 points

Hollow bars mark forward-looking points. How the balance works

Positive

  • Moderate pointNo dose-limiting toxicities or adverse events causing discontinuation were reported among the first 10 patients.
  • Moderate point. Forward-looking: it has not happened yet and may not happen.Randomized Phase 2 study is targeted by Cerenome for 2027.
  • Minor pointLM progression was 0/5 at three and six months and 1/4 at nine months among evaluable patients.
  • Minor point79.2 mCi cumulative activity in one patient exceeded the prior single-dose study's highest administration of 75 mCi.
  • Minor pointEstimated cumulative LM absorbed dose reached 207 Gy in one patient completing three 26.4 mCi administrations.
5 minor points
  • Minor pointFive patients completing three 13.2 mCi administrations received cumulative LM absorbed doses of 85–137 Gy.
  • Minor pointRepeat-dose consistency showed median within-patient variation of 8% for absorbed dose per mCi and 12% for CSF effective half-life.
  • Minor pointThree patients reached zero tumor cells/mL; two remained at zero at latest assessments, while the third later progressed.
  • Minor pointMedian blood-derived marrow absorbed dose was 0.023 Gy per administration, with a range of 0.010–0.41 Gy.
  • Minor point. Forward-looking: it has not happened yet and may not happen.Continued dose escalation and enrollment are planned to define recommended multiple-dose regimens.

Negative

  • Minor pointAll 10 patients had treatment-emergent adverse events: nausea 60%; headache, decreased lymphocytes and decreased white blood cells 40% each.
  • Minor pointGrade 3 treatment-related nausea occurred in one patient and resolved within five days.
  • Minor pointOne serious adverse event, shortness of breath, occurred and was considered unrelated to treatment.
  • Minor pointPreliminary open-label findings involve differing cancers, treatment histories and follow-up; three patients received concurrent systemic treatment.
  • Minor pointLandmark analyses exclude unevaluable patients and do not establish a progression-free or overall survival benefit.
  • Minor point. Forward-looking: it has not happened yet and may not happen.2027 Phase 2 target depends on continued clinical progress and regulatory alignment.

News Explained

The observations quantify LM absorbed dose at 207 Gy in one patient and show sustained zero-cell samples in two patients, alongside later progression in another.

The ongoing open-label dose-escalation study reports cumulative absorbed-dose estimates and serial CSF tumor-cell observations alongside administered-activity and landmark-progression findings.

One patient completing three 26.4 mCi administrations received an estimated cumulative LM-compartment absorbed dose of 207 Gy, with no dose-limiting toxicities; five patients completing three 13.2 mCi administrations received estimated cumulative doses of 85–137 Gy. The median blood-derived marrow absorbed dose was 0.023 Gy per administration, with a range of 0.010–0.41 Gy.

Among three patients with detectable tumor cells at baseline, later samples showed zero tumor cells per mL; two remained at zero at their latest assessments, 9.2 and 2.3 months after the first dose, while the third later had rising counts and MRI-confirmed LM progression.

Key Figures

LM progression at three and six months: 0/5 at each landmark LM progression by nine months: 1 of 4 evaluable patients Cumulative LM compartment absorbed dose: Estimated 207 Gy +4 more
LM progression at three and six months
0/5 at each landmark
Among evaluable patients
LM progression by nine months
1 of 4 evaluable patients
Nine-month landmark
Cumulative LM compartment absorbed dose
Estimated 207 Gy
One patient after three 26.4 mCi administrations
Cumulative LM compartment absorbed doses
85–137 Gy
Five patients completing three administrations at 13.2 mCi per dose
Within-patient coefficient of variation
Median 8%
Absorbed dose per mCi across repeat administrations
Blood-derived marrow absorbed dose
Median 0.023 Gy per administration (range, 0.010–0.41 Gy)
Estimated exposure
Total administered activity
79.2 mCi
One patient after three 26.4 mCi doses

Key Terms

intraventricular, dose-limiting toxicities, dosimetry, spect/ct
4 terms
intraventricular medical
"repeated intraventricular dosing of REYOBIQ"
Located or occurring inside a ventricle — the hollow pumping chambers of the heart or the fluid-filled cavities in the brain. For investors, intraventricular matters because treatments or complications in these spaces often require specialized delivery methods, devices, or procedures, increasing development complexity, regulatory scrutiny, and potential costs; think of it like delivering a package directly into a room rather than to a building’s front door, which changes logistics and risk.
dose-limiting toxicities medical
"No dose-limiting toxicities or adverse events leading to treatment discontinuation"
Dose-limiting toxicities are the harmful side effects seen in early clinical trials that are severe enough to stop researchers from raising a drug’s dose. Like a car’s speed limiter marking the safe top speed, DLTs define the maximum tolerable dose, and they matter to investors because they determine whether a medicine can reach effective levels, influence development timelines, costs, and regulatory chances, and thus affect a drug’s commercial prospects.
dosimetry technical
"treatment exposure, safety, dosimetry, LM progression status"
Dosimetry is the measurement and calculation of how much ionizing radiation is absorbed by people, tissues, or devices, similar to a thermostat tracking temperature in different rooms to know where and how much heat is present. Investors should care because accurate dosimetry underpins safety, treatment effectiveness, regulatory approval, and liability for products and services that use radiation—affecting market access, costs, and commercial risk.
spect/ct medical
"SPECT/CT imaging in the patient who completed three 26.4 mCi administrations"
SPECT/CT is a medical imaging scan that combines two types of pictures: one that shows how organs and tissues are working (SPECT) and one that shows detailed anatomy (CT), layered together like a weather radar over a street map. For investors, it matters because clearer, combined images can improve diagnosis, guide treatment choices, and drive demand for imaging equipment, radiopharmaceuticals, and clinical services—factors that influence healthcare revenues and reimbursement trends.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

No dose-limiting toxicities in the first 10 patients; consistent and reliable dosing of a targeted radiopharmaceutical; early disease control signal in line with existing data

HOUSTON, Nov. 16, 2026 (GLOBE NEWSWIRE) -- Cerenome, Inc. (Nasdaq: CNSY) (“Cerenome” or the “Company”), a CNS oncology company advancing an integrated platform that combines precision diagnostics, targeted radiopharmaceuticals, and artificial intelligence, today announced interim data from its ongoing ReSPECT-LM study of repeated intraventricular dosing of REYOBIQ™ (rhenium Re186 obisbemeda) in patients with leptomeningeal metastases (LM). The data were presented as a poster on November 13, 2026, during the Society for Neuro-Oncology (SNO) 31st Annual Meeting and Education Day.

The poster reports treatment exposure, safety, dosimetry, LM progression status, and cerebrospinal fluid (CSF) tumor-cell findings for the first 10 patients treated. No dose-limiting toxicities or adverse events leading to treatment discontinuation have been reported. To date, one patient has received three 26.4 mCi doses, for a total administered activity of 79.2 mCi. This exceeds the highest activity given as a single administration in the prior single-dose ReSPECT-LM study (75 mCi). Furthermore, imaging showed the radiation dose delivered to the LM compartment was consistent from one treatment to the next within each patient, varying by a median of 8%. These levels are consistent with previously reported Phase 1 single-dose data. Dose escalation is ongoing.

No LM progression was documented by the three- and six-month landmarks among evaluable patients (0/5 at each landmark), and progression was documented in 1 of 4 evaluable patients by nine months.

“These interim findings support the feasibility and early tolerability of fractionated REYOBIQ dosing as a way to deliver a higher cumulative radiation dose to the LM compartment,” said Eric J. Daniels, M.D., Cerenome’s Chief Operating Officer. “The LM progression findings among evaluable patients are encouraging, alongside the absence of dose-limiting toxicities to date and consistent radiation delivery across repeat administrations. Our focus now is on continued dose escalation and enrollment to define recommended multiple-dose regimens in support of a future randomized study.”

Interim ReSPECT-LM Findings

Of the 10 patients, six received 13.2 mCi per administration and four received 26.4 mCi per administration. Primary cancers included melanoma (4), breast cancer (3), non-small cell lung cancer (1), ovarian cancer (1), and neuroendocrine cancer (1). Nine patients had received prior LM therapy, and three were receiving concurrent systemic treatment.

  • Safety: No dose-limiting toxicities or adverse events leading to discontinuation have been observed. One patient had Grade 3 treatment-related nausea, which resolved within five days. The only serious adverse event, shortness of breath occurring in a single subject, was considered unrelated to treatment. All 10 patients had at least one treatment-emergent adverse event; the most common were nausea (60%), headache (40%), decreased lymphocyte count (40%), and decreased white blood cell count (40%).
  • Landmark LM progression findings: No LM progression was documented by three or six months among evaluable patients (0/5 at each landmark). By nine months, LM progression was documented in 1 of 4 evaluable patients. Evaluability was determined by principal investigator review of available records, based on documented progression on or before the landmark or adequate disease-assessment follow-up establishing LM status through that landmark. Patients with insufficient follow-up, or who died from primary disease before the landmark without prior LM progression, were excluded. These descriptive findings are not progression-free survival estimates.
  • CSF tumor-cell findings: Serial monitoring with Cerenome’s CNSide® documented tumor-cell reductions in individual patients. Three patients with detectable tumor cells at baseline later had samples with zero tumor cells/mL. Two of them remained at zero tumor cells/mL at their latest assessments, 9.2 and 2.3 months after the first dose, respectively. The third later had a rise in tumor-cell counts and MRI-confirmed LM progression, nearly 4 months after the third dose of REYOBIQ.
  • High cumulative absorbed doses: The first patient to complete three administrations at 26.4 mCi per dose received an estimated cumulative LM compartment absorbed dose of 207 Gy, with no dose-limiting toxicities. Five patients completing three administrations at the lowest dose level, 13.2 mCi per dose, received cumulative LM compartment absorbed doses of 85–137 Gy, again consistent with previously observed Phase 1 data.
  • Consistent repeat-dose delivery: In patients who received repeat administrations, the absorbed dose per mCi varied little from dose to dose (median within-patient coefficient of variation, 8%), as did the CSF effective half-life (12%). Dosimetry was consistent with the prior single-dose ReSPECT-LM experience, supporting the feasibility of repeat dosing. SPECT/CT imaging in the patient who completed three 26.4 mCi administrations showed a similar distribution of activity after each dose.
  • Low estimated bone marrow exposure: The median blood-derived marrow absorbed dose was 0.023 Gy per administration (range, 0.010–0.41 Gy). This low level of blood exposure is important to avoid potential cytopenias and further supports continued investigation of local LM compartmental delivery.

“The lack of documented LM progression among evaluable patients at the three- and six-month landmarks is early and encouraging, particularly in a population in which most patients had received prior LM therapy,” said Andrew J. Brenner, M.D., Ph.D., Professor of Medicine at Mays Cancer Center at UT Health San Antonio and lead author of the poster. “The ability to deliver substantial cumulative radiation doses with consistent repeat-dose delivery and low estimated marrow exposure supports further evaluation. These findings remain preliminary, and continued enrollment and follow-up are needed to determine the clinical activity of this regimen.”

These preliminary findings come from an ongoing, open-label dose-escalation study. Patients had different primary cancers, treatment histories, and lengths of follow-up, and some received concurrent systemic therapy. The landmark analyses include only patients evaluable at each time point and do not establish a progression-free or overall survival benefit.

As previously announced, Cerenome is targeting a Phase 2 randomized study in 2027, subject to continued clinical progress and regulatory alignment.

Poster Presentation

Abstract CodeCTNI-40
Poster TitleRepeated Intraventricular Rhenium-186 Obisbemeda (186RNL) in Leptomeningeal Metastases: Interim Dosimetry, Safety, and CSF Tumor Cell Response From the ReSPECT-LM Multiple-Dose Study
Date and TimeFriday, November 13, 2026, 7:30-9:30 p.m. ET
LocationExhibit Hall D & E, Pennsylvania Convention Center, Philadelphia


About ReSPECT-LM

ReSPECT-LM (NCT07098806) is an open-label, multicenter Phase 1 study of repeated intraventricular administration of REYOBIQ in adults with LM from solid tumors. REYOBIQ is delivered into the LM compartment through an Ommaya reservoir. The study is evaluating three dose levels (13.2, 26.4 and 44.1 mCi) and three dosing intervals (every 14, 28 or 56 days) across eight planned cohorts, with three administrations per participant. It is designed to assess safety, dosimetry and activity, and to identify a recommended multiple-dose regimen.

About REYOBIQ™
REYOBIQ (rhenium Re186 obisbemeda) is an investigational injectable radiotherapeutic in which the radioisotope rhenium-186 is chelated and trapped inside a nanoliposome. It is designed to deliver targeted, high-dose beta radiation directly to tumors through local delivery, such as convection-enhanced delivery or an intraventricular (Ommaya) catheter, while keeping exposure to the rest of the body low.

REYOBIQ is being evaluated for the treatment of leptomeningeal metastases, recurrent glioblastoma, and pediatric brain cancers in the ReSPECT-LM, ReSPECT-GBM, and ReSPECT-PBC clinical trials, respectively. Results from the multicenter Phase 1 ReSPECT-GBM trial were published in Nature Communications in 2025 (Brenner AJ, et al. Nat Commun. 2025;16:2079). REYOBIQ is investigational and has not been approved by the U.S. Food and Drug Administration or any other regulatory authority for any use. ReSPECT-GBM is supported by an award from the National Cancer Institute (NCI), part of the U.S. National Institutes of Health (NIH), and ReSPECT-LM is funded by a $17.6 million grant from the Cancer Prevention & Research Institute of Texas (CPRIT). The Company's ReSPECT-PBC clinical trial for pediatric brain cancer is supported by a $3 million grant from the U.S. Department of Defense's Peer Reviewed Cancer Research Program.

About Cerenome
Cerenome (Nasdaq: CNSY) is a CNS oncology company advancing an integrated platform that combines precision diagnostics, targeted therapeutics, and artificial intelligence to improve outcomes for patients with central nervous system cancers. The CNSide® CSF diagnostics platform combines cellular and molecular testing to support the detection, characterization, and longitudinal assessment of cancers involving the CNS.

Its lead therapeutic platform, REYOBIQ™ (rhenium Re186 obisbemeda), is being evaluated in clinical trials for leptomeningeal metastases, recurrent glioblastoma, and pediatric brain cancers. The data & artificial intelligence platform is designed to integrate diagnostic, molecular, imaging, and clinical data into actionable insights that support precision oncology and therapeutic innovation.

By integrating commercial diagnostics, targeted therapeutics, proprietary longitudinal data, and artificial intelligence within a single organization, Cerenome is building a differentiated CNS oncology platform designed to improve patient care while creating long-term shareholder value. For more information, visit https://www.cerenome.com.

Forward-Looking Statements

This press release contains statements that may be deemed “forward-looking statements” within the meaning of U.S. securities laws, including statements regarding commercialization, clinical trials and upcoming developments. All statements in this press release other than statements of historical fact are forward-looking statements. These forward-looking statements may be identified by future verbs, as well as terms such as “expected,” “planning,” “future,” “targeting,” “continue,” and similar expressions or the negatives thereof. Such statements are based upon certain assumptions and assessments made by management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. These statements include, without limitation, statements regarding the development and clinical utility of the ReSPECT-LM study and future randomized studies regarding ReSPECT-LM.

Investor Contact
CORE IR
IR@cerenome.com


FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Cerenome's interim ReSPECT-LM study show about repeat-dose REYOBIQ safety?

No dose-limiting toxicities or adverse events leading to treatment discontinuation were reported among the first 10 patients. All patients had at least one treatment-emergent adverse event. One patient experienced Grade 3 treatment-related nausea, which resolved within five days.

What were the LM progression results in Cerenome's ReSPECT-LM study?

No LM progression was documented among evaluable patients at three or six months, with 0/5 at each landmark; progression was documented in 1 of 4 evaluable patients by nine months. These descriptive findings are not progression-free survival estimates and do not establish a survival benefit.

Which patients counted in Cerenome's ReSPECT-LM landmark progression analyses?

Evaluability required investigator-reviewed records showing progression on or before the landmark or adequate follow-up establishing LM status through it. Patients with insufficient follow-up, or who died from primary disease before the landmark without prior LM progression, were excluded.

What dosing schedules is Cerenome evaluating in the ReSPECT-LM study?

ReSPECT-LM evaluates 13.2, 26.4 and 44.1 mCi dose levels and intervals of every 14, 28 or 56 days across eight planned cohorts, with three administrations per participant. REYOBIQ is delivered into the LM compartment through an Ommaya reservoir.

Keep reading